AstraZeneca and Leo Pharma receive CHMP backing for psoriasis therapy

Pharmaceutical Company Product News

AstraZeneca and its collaborative partner Leo Pharma have received a recommendation for European regulatory approval of a new treatment for psoriasis.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the drug brodalumab as a treatment for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.

“AstraZeneca and Leo Pharma have received a CHMP recommendation for European approval of brodalumab as a treatment for moderate to severe plaque psoriasis.“

Brodalumab is the first fully human monoclonal antibody therapy that selectively targets the IL-17 receptor, allowing the compound to effectively block the biological activity of several proinflammatory IL-17 cytokines, which are important in psoriasis.

AstraZeneca granted Leo Pharma exclusive rights to develop and commercialise brodalumab in Europe in a deal agreed in July 2016. Since then, the compound has received approvals from regulators in the US and Japan.

Following the CHMP's positive opinion, brodalumab's application will now be reviewed by the European Commission, which will make a final decision on whether to approve the drug over the coming months.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news

Tags